Oxymetazoline

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 576146

CAS#: 1491-59-4

Description: Oxymetazoline is a selective α1 adrenergic receptor agonist and α2 adrenergic receptor partial agonist.


Chemical Structure

img
Oxymetazoline
CAS# 1491-59-4

Theoretical Analysis

MedKoo Cat#: 576146
Name: Oxymetazoline
CAS#: 1491-59-4
Chemical Formula: C16H24N2O
Exact Mass: 260.1889
Molecular Weight: 260.38
Elemental Analysis: C, 73.81; H, 9.29; N, 10.76; O, 6.14

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: H 990; H990; H-990; Oxymetazoline

IUPAC/Chemical Name: Phenol, 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1,1-dimethylethyl)-2,4-dimethyl-

InChi Key: WYWIFABBXFUGLM-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)

SMILES Code: Cc1cc(c(O)c(C)c1CC2=NCCN2)C(C)(C)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: to be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 260.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kirtsreesakul V, Khanuengkitkong T, Ruttanaphol S. Does oxymetazoline increase the efficacy of nasal steroids in treating nasal polyposis? Am J Rhinol Allergy. 2016 May;30(3):195-200. doi: 10.2500/ajra.2016.30.4294. PubMed PMID: 27216350.

2: Gopalakrishnan S, Sodhi K. Recurrent Apnea in a Neonate Following Intranasal Oxymetazoline. Indian Pediatr. 2016 Apr;53(4):353. PubMed PMID: 27156558.

3: Menezes GA, Araujo Júnior E, Lopes J, Belmonte S, Tonni G, Werner H. Prenatal diagnosis and physical model reconstruction of agnathia-otocephaly with limb deformities (absent ulna, fibula and digits) following maternal exposure to oxymetazoline in the first trimester. J Obstet Gynaecol Res. 2016 Apr 17. doi: 10.1111/jog.13014. [Epub ahead of print] PubMed PMID: 27087030.

4: Thongngarm T, Assanasen P, Pradubpongsa P, Tantilipikorn P. The effectiveness of oxymetazoline plus intranasal steroid in the treatment of chronic rhinitis: A randomised controlled trial. Asian Pac J Allergy Immunol. 2016 Mar;34(1):30-7. doi: 10.12932/AP0649.34.1.2016. PubMed PMID: 26994623.

5: Hersh EV, Pinto A, Saraghi M, Saleh N, Pulaski L, Gordon SM, Barnes D, Kaplowitz G, Bloom I, Sabti M, Moore PA, Lee S, Meharry M, He DY, Li Y. Double-masked, randomized, placebo-controlled study to evaluate the efficacy and tolerability of intranasal K305 (3% tetracaine plus 0.05% oxymetazoline) in anesthetizing maxillary teeth. J Am Dent Assoc. 2016 Apr;147(4):278-87. doi: 10.1016/j.adaj.2015.12.008. Epub 2016 Jan 25. PubMed PMID: 26822100.

6: Teixeira MS, Alper CM, Martin BS, Helal N, Doyle BM, Doyle WJ. Oxymetazoline Applied Topically to the Nasal Mucosa Decreases Trans-Mucosal Nitrous Oxide Exchange for the Middle Ear. Ann Otol Rhinol Laryngol. 2016 May;125(5):400-7. doi: 10.1177/0003489415617776. Epub 2015 Nov 26. PubMed PMID: 26611245; PubMed Central PMCID: PMC4853169.

7: Nordt SP, Vivero LE, Cantrell FL. Not Just a Drop in the Bucket-Inversion of Oxymetazoline Nasal Decongestant Container Increases Potential for Severe Pediatric Poisoning. J Pediatr. 2016 Jan;168:240-1. doi: 10.1016/j.jpeds.2015.09.067. Epub 2015 Oct 30. PubMed PMID: 26522979.

8: Valerieva A, Popov TA, Staevska M, Kralimarkova T, Petkova E, Valerieva E, Mustakov T, Lazarova T, Dimitrov V, Church MK. Effect of micronized cellulose powder on the efficacy of topical oxymetazoline in allergic rhinitis. Allergy Asthma Proc. 2015 Nov-Dec;36(6):e134-9. doi: 10.2500/aap.2015.36.3879. Epub 2015 Jun 29. PubMed PMID: 26133030.

9: Kishore A, Blake L, Wang C, Ba S, Gross G. Evaluating the Effect of Sinex® (0.05% Oxymetazoline) Nasal Spray on Reduction of Nasal Congestion Using Computational Fluid Dynamics. J Biomech Eng. 2015 Aug;137(8):081011. doi: 10.1115/1.4030825. Epub 2015 Jun 23. PubMed PMID: 26065640.

10: Phillips CB, Huang CC. Topical oxymetazoline hydrochloride 0.05% as a strategy to reduce intraoperative wound oozing in Mohs micrographic surgery. Dermatol Surg. 2015 Jun;41(6):749-50. doi: 10.1097/DSS.0000000000000362. PubMed PMID: 25984903.